• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: B.BRAUN MEDICAL SAS CESLITE; ACCESS PORT SYSTEM

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

B.BRAUN MEDICAL SAS CESLITE; ACCESS PORT SYSTEM Back to Search Results
Model Number 4430395
Device Problem Expulsion (2933)
Patient Problem Impaired Healing (2378)
Event Date 03/01/2024
Event Type  Injury  
Manufacturer Narrative
Note: product reference (b)(4) is not cleared for sales in the usa, but it is similar to a product reference cleared under #510k130576.Batch history review: batch unknown.Investigation results: the device was not returned for evaluation.However a picture of the event was forwarded.We can see the access port implanted in the patient's chest: the access port housing is visible through the skin.The patient skin/scare over the access port is pierced and dry.No swelling is visible.We can see that the access port housing is located under the implantation scar.Conclusion: the access port exteriorization observed is a known complication of access port implantation.The image received seems to show that two factors could have contributed to this incident: - the fact that the access port housing was implanted just under the skin incision, not at one centimeter of the skin incision as recommended.The ifu specifies: vi-1-1 k) "ensure that the skin incision is 1 cm from the injection site." - the fact that the access port was implanted too superficially: the ifu specifies: vi-1-1 "f) prepare the port pocket at the chosen site, the port should lie approximately 1/2 - 1 cm below the skin surface away from the injection site." this is a rare incident not directly imputable to the device, no corrective action is envisaged for the moment.
 
Event Description
Patient undergoing systemic management with highly toxic chemotherapy with flot scheme, comes for 3rd cycle administration showing evidence of dehiscence of the pocket wound of the implantable catheter with exposure of the device.It is not possible to use this access under these conditions, patient would require hospitalization to change the catheter and complete infusion of 5 fluorouracil.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
CESLITE
Type of Device
ACCESS PORT SYSTEM
Manufacturer (Section D)
B.BRAUN MEDICAL SAS
26 rue armengaud
saint cloud, 92210
FR  92210
Manufacturer (Section G)
B.BRAUN MEDICAL SAS FRANCE
30 avenue des temps modernes
chasseneuil du poitou 86360
FR   86360
Manufacturer Contact
catherine boismenu
30 avenue des temps modernes
chasseneuil du poitou 86360
FR   86360
MDR Report Key19141759
MDR Text Key340567086
Report Number9612452-2024-00013
Device Sequence Number1
Product Code LJT
Combination Product (y/n)N
Reporter Country CodeCO
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,User Facility
Reporter Occupation Other
Type of Report Initial
Report Date 04/19/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model Number4430395
Was Device Available for Evaluation? No
Initial Date Manufacturer Received Not provided
Initial Date FDA Received04/19/2024
Was Device Evaluated by Manufacturer? No
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Hospitalization;
Patient Age34 YR
Patient SexFemale
-
-